A meta-analysis including 2552 thyroid cancer patients from 17 studies reported an overall RAS mutation prevalence of 35.4% (95% CI: 22.7–50.7%), with NRAS being the most frequent subtype (69.5%), followed by HRAS (25.8%) and KRAS (6.9%). The gene discussed is HRAS; the disease is thyroid gland carcinoma.